Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.
Noha Abdel-WahabMaria E Suarez-AlmazorPublished in: Expert review of clinical immunology (2024)
In light of the evolving landscape of cancer immunotherapy, there is a compelling need for prospective longitudinal studies to enhance understanding and inform clinical management strategies for rheumatic irAEs.